Proof of concept of triple COMBI therapy to prohibit MPN progression to AML.
Hans Carl HasselbalchVibe SkovLasse KjaerMorten Kranker LarsenPublished in: British journal of haematology (2023)
Patients with accelerated or blast phase myeloproliferative neoplasms have a dismal prognosis. The report by de Castro et al. provides important information on the rationale and prospect for a novel therapeutic approach combining interferon-alpha2 with 5-azacytidine and a JAK1-2 inhibitor (ruxolitinib) to be explored in well-designed clinical trials. Commentary on: Castro et al. Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia. Br J Haematol 2023 (Online ahead of print). doi: 10.1111/bjh.19107.
Keyphrases
- clinical trial
- dendritic cells
- acute myeloid leukemia
- health information
- liver failure
- stem cells
- bone marrow
- epithelial mesenchymal transition
- respiratory failure
- low grade
- drug induced
- healthcare
- immune response
- phase ii
- randomized controlled trial
- allogeneic hematopoietic stem cell transplantation
- mesenchymal stem cells
- current status
- signaling pathway
- cancer stem cells
- smoking cessation
- high grade
- replacement therapy